The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | IberDd in patients with newly diagnosed myeloma: a subgroup analysis by renal function
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, briefly discusses a subgroup analysis by renal function of the Phase I/II CC-220-MM-001 trial (NCT02773030) evaluating iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma (MM). The analysis suggests that the presence of renal insufficiency does not affect clinical outcomes when treating this patient population with the IberDd regimen. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
